ArticleEULAR rheumatology open2026
Healthcare providers' awareness and knowledge of recommendations on cardiovascular risk management in people with rheumatic and musculoskeletal diseases: a survey study.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient awareness and perception of cardiovascular risk in rheumatic and musculoskeletal diseases: results from an international survey.EULAR rheumatology open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) have increased cardiovascular (CV) risk. European Alliance of Associations for Rheumatology (EULAR) issued CV risk management recommendations in 2015/2016 and 2022, but healthcare providers' (HCPs') awareness and their implementation in clinical practice are unknown. This study aims to assess HCP awareness of the EULAR CV recommendations and barriers to their implementation. Methods: A cross-sectional survey was distributed via social media to all HCPs involved in treating patients with RMDs. Data on demographics, awareness of the 2015/2016 and 2022 recommendations, and perceived implementation barriers were collected. The survey was endorsed by the EULAR Study Group on Cardiovascular Involvement in Inflammatory Arthritis. Results: Of 226 complete responses, 54% were hospital rheumatologists and 36% had 5 to 15 years of experience. Overall, 67% knew both recommendation sets. Knowledge scores were higher among those aware of both recommendations compared with those who knew neither. Most respondents (83%) recognised that platelet inhibitors are not recommended for primary prevention; only 8% identified the role of low systemic lupus erythematosus disease activity. Nearly all (96%) endorsed corticosteroid minimisation. Half viewed rheumatologists as primarily responsible for CV risk management; 16% knew the 1.5 multiplication factor for rheumatoid arthritis risk scoring. None correctly noted that antihypertensives and statins can be used as in the general population. Barriers included time constraints (62%), insufficient knowledge (37%), and lack of local protocols (14%). Conclusions: Despite moderate awareness of EULAR CV recommendations, substantial knowledge gaps and practical barriers persist, indicating the need for focused education and improved clinical pathways to enhance CV risk management in RMD care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.